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Abstract
Background: Quality of life as an endpoint in a clinical study may be sensitive to the value set used to derive a single
score. Focusing on patients’ actual valuations in a clinical study, we compare different value sets for the EQ-5D-3L and
assess how well they reproduce patients’ reported results.
Methods: A clinical study comparing inpatient (n = 98) and outpatient (n = 47) rehabilitation of patients after an acute
coronary event is re-analyzed. Value sets include: 1. Given health states and time-trade-off valuation (GHS-TTO)
rendering economic utilities; 2. Experienced health states and valuation by visual analog scale (EHS-VAS). Valuations are
compared with patient-reported VAS rating. Accuracy is assessed by mean absolute error (MAE) and by Pearson’s
correlation ρ. External validity is tested by correlation with established MacNew global scores. Drivers of differences
between value sets and VAS are analyzed using repeated measures regression.
Results: EHS-VAS had smaller MAEs and higher ρ in all patients and in the inpatient group, and correlated best with
MacNew global score. Quality-adjusted survival was more accurately reflected by EHS-VAS. Younger, better educated
patients reported lower VAS at admission than the EHS-based value set.
EHS-based estimates were mostly able to reproduce patient-reported valuation. Economic utility measurement is
conceptually different, produced results less strongly related to patients’ reports, and resulted in about 20 % longer
quality-adjusted survival.
Conclusion: Decision makers should take into account the impact of choosing value sets on effectiveness results. For
transferring the results of heart rehabilitation patients from another country or from another valuation method, the
EHS-based value set offers a promising estimation option for those decision makers who prioritize patient-reported
valuation. Yet, EHS-based estimates may not fully reflect patient-reported VAS in all situations.
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Background
Quality of life is a key endpoint in a number of clinical
studies. Its measurement requires collection of data on
the dimensions and items by which quality of life is
being described. In order to gain an overall result, an ag-
gregation step is needed that can be performed by a
researcher—such as defining the average across all items
as the aggregate—or by an individual’s valuation express-
ing subjective summary assessment.
This paper considers alternative options to aggregate
results by the response of individuals. The valuation of
health states is known to vary widely between countries
[1–3]. Clinical studies may include patients from differ-
ent countries, which may influence quality of life results
by varying valuations. In addition, health care decision
makers and regulators may question whether valuation
is appropriate if it has been derived from another popu-
lation, or by another method than they require. In these
cases, results may incur methodological biases when
quantifying quality of life endpoints. If access to original
study data is provided, the impact of the required ap-
proach for valuation can be analyzed by re-valuing
health states reported by estimates of the respective
value from a population study, that is by using a so-
called value set.
Approaches to valuing quality of life may be crucial
for study results. Methodologically, valuation can differ
in various aspects. Patients or the general population
may be asked to perform the valuation. For direct valu-
ation, the visual analog scale (VAS) may be used, or a
choice-based method such as the time-trade-off method
(TTO) [4, 5]. The health states being valued could be
the individual’s own, just experienced health state (EHS),
or they could be hypothetical, given health states (GHS).
When referring to quality-adjusted life years (QALYs) in
economic evaluation studies, quality of life measures are
most often integrated using a choice-based valuation of
GHS. Such utilities reflect the ex-ante preferences of in-
dividuals with regard to health. Typically, they are elic-
ited at the population level, thought to reflect
population preferences, and thus used to inform deci-
sions on allocating health care resources [6]. This pro-
cedure is well established in decision practice: for
example, the UK National Institute for Health and Care
Excellence (NICE) has been using this type of informa-
tion for more than 15 years.
Critical voices have also been raised concerning the
theoretical foundations of using such community prefer-
ences for allocating health care funds [7]. In addition,
some jurisdictions require measurement of patient bene-
fit as the primary indicator in order to decide upon
health care technologies. In Sweden, the Dental and
Pharmaceutical Benefits Agency prefers EHS-based valu-
ation over GHS-based valuation [8]. In Germany, the
Social Code, Book V § 35 1(b) defines patient relevant
benefit, including quality of life, as the key effect criterion;
this does not refer to ex-ante preferences of the
population.
In recent years, several EHS-based value sets have been
developed that estimate the individual’s valuation of his/
her own health state [8–10]. EHS-based value sets have
been used in a range of epidemiological and clinical stud-
ies, including diabetes [11], stroke [12], hip replacement
[13, 14], inflammatory bowel disease [15], and chronic
diseases [16]. EHS-based value sets predict how an aver-
age person experiencing a health state would value this
health state. For decision makers who focus on patient
benefit, EHS-based value sets may thus provide a substitu-
tive valuation in situations where context-specific, patient-
reported valuation is lacking. As a pre-condition to such
substitution in quality of life measurement, the value set
has to accurately predict the patient’s valuation as well as
the valuation of patient subgroups, such as patients in the
treatment arms of a trial.
This paper assumes the perspective of a decision
maker who requests evidence on patient relevant benefit
and thus would prefer patients to directly value their
own health states. If this is not available, GHS-based and
EHS-based value sets derived from population studies
could provide options for a second-best solution. In
order to assess the performance of such second-best
choices, the paper uses quality of life data from a pub-
lished, clinical study of heart rehabilitation patients. As
reference for the endpoint of quality of life, patient-
reported valuations are taken. The paper starts out from
the counterfactual assumption that the latter are lacking
and thus uses two value sets for valuation. Indeed, the
clinical study has collected patient-reported valuations.
The paper then investigates how well the value sets re-
flect patients’ valuations.
Methods
The clinical study re-analyzed here compared inpatient
and outpatient rehabilitation of patients following an acute
cardiac event. The study was conducted in Germany and
labeled SARAH (Stationäre versus ambulante Rehabilition
nach akutem Herzereignis). Results have been presented
elsewhere, showing that, over 3 weeks of intervention and
a 12-month follow-up, inpatient and outpatient rehabilita-
tion did not differ significantly with regard to the primary
medical endpoint of event-free survival, combining myo-
cardial infarction, stroke, heart failure, life-threatening
rhythm events, unstable angina, and death [17], and also
did not differ significantly with regard to generic quality of
life and cost-effectiveness [18]. The study was carried out
according to the Declaration of Helsinki, and was
approved by the Institutional Ethics Board of Ulm Univer-
sity. Written informed consent was obtained from all
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participants. With inpatient rehabilitation representing
standard care in this context, feasibility of randomization
had to be clarified first. The study thus used a comprehen-
sive cohort design [19]: Patients who had agreed to par-
ticipate were offered the option of being randomized and,
if they refused, were offered the option to choose a treat-
ment arm. Included were patients below 66 years of age,
with myocardial infarction occurring less than 3 months
before admission to the rehabilitation hospital. Some 163
patients met the inclusion criteria and were recruited.
Only four patients agreed to randomization; of the rest,
112 patients starting in the inpatient rehabilitation arm
and 51 patients receiving outpatient rehabilitation were al-
located on a preference basis. Patient enrolment started in
2002 and study follow-up ended in 2005. For the meth-
odological re-analysis in the present study, all patients
with quality of life measurements included in the cost-
effectiveness study were used. To compare valuation
measurement, we restricted this study to observed mea-
surements, disregarding imputation.
Quality of life was measured using the EQ-5D-3L, a
standardized instrument that is available in more than
170 official language versions [20]. A comprehensive re-
view on the use of the EQ-5D-3L in cardiovascular dis-
eases found 60 application studies and ten studies that
analyzed validity or reliability, with the results clearly
supporting this use. However, results were not stratified
with regard to the use of different types of valuation
methods [21]. For German heart rehabilitation patients,
the EQ-5D-3L has also been shown to be a valid and re-
liable tool [22]. In the re-analyzed study, patients were
requested to fill in the EQ-5D-3L descriptive system and
the VAS at six points in time: admission, discharge, and
after 3, 6, 9, and 12 months of follow-up (FU).
We tested the use of two national value sets that have
been derived from German population studies [9, 23].
They differ with regard to the key methodological
characteristics of valuing quality of life mentioned above,
including the additional characteristic of scale adjust-
ment (Table 1). The traditional health economic ap-
proach based on GHS-TTO uses the valuation of death
in order to anchor the lower end of the scale. The EHS-
based approach cannot incorporate anchoring for the
state of being dead. For comparability, all the results re-
ported in this paper have been transferred to the 0 to
100 scale.
A patient’s VAS valuation serves as the reference for
patient benefit. Performance of the two value sets was
analyzed in six steps (Additional file 1: Table S1): com-
parison of raw values, deviations from the reference, cor-
relation with the reference and with an accepted medical
endpoint, comparison of quality-adjusted survival, and
identification of factors influencing differences from the
reference.
Mean absolute error (MAE) of value sets compared
with VAS values reported by patients are investigated
over the six measurement points. For correlation be-
tween patients’ VAS and value sets, Pearson correlation
coefficients ρ are analyzed for absolute valuations as well
as differences in valuations over time—the latter are a
key indicator of effectiveness trend. To estimate confi-
dence intervals, Bootstrap methods were applied for the
correlation coefficients. Correlations were investigated
for all patients, for the two study arms of inpatients and
outpatients, and for the subgroups of the lower and
upper quartiles of patients with regard to VAS valuation
reported at admission.
External validity is analyzed using an acknowledged clin-
ical measure of quality of life in cardiac patients: the Mac-
New, specifically its global score [24]. For all patients,
Pearson correlations with the MacNew global score are
calculated for patients’ own valuations as well as for the
two value sets, again for both absolute valuations reported
as well as differences in valuations over time.
Table 1 Approaches studied to value quality of life
Valuation Patients’ VAS (reference) GHS-TTO Germany EHS-VAS Germany
Who values? Patient X
Population (value set) X X
What is being valued? Experienced health state X X
Hypothetical health state X
How is it valued? Directly (VAS) X X
Choice-based (TTO) X
Scale adjustment None X X
Anchoring for death X
Endpoint when multiplied by time QALYs (utilities) X
Quality-adjusted survival X X
Legend: VAS visual analog scale, GHS given health states, EHS experienced health states, TTO time-trade-off method, GHS-TTO Germany and EHS-VAS Germany represent
two national value sets [6, 19]
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Overall treatment effect in terms of quality-adjusted
survival is captured by multiplying value by the duration
it applies to. In case of the choice-based GHS-Germany,
this produces traditional quality-adjusted life years
(QALYs). For patients’ VAS and EHS-Germany, quality-
adjusted survival is based upon experienced health and
thus differs from the ex-ante concept of utility-based
QALYs. Analyses are conducted for all patients, for the
inpatient and outpatient rehabilitation arms of the clin-
ical study, and for the upper and lower quartiles of pa-
tients in terms of quality of life reported. These
stratifications are intended to reflect the increasing rele-
vance of analyzing patients by subgroups, which is found
especially in patient benefit assessment in German drug
regulation [25].
Finally, we explain differences between the two value
sets and patients’ own reports by repeated measures re-
gression. Explanatory variables include socioeconomic
ones such as age and sex, education, and family status as
well as health determinants such as smoking and base-
line MacNew global score. All effects are further tested
on differences with respect to the time point at which
average differences were largest.
Results
The sample in this study comprised a total of 145 pa-
tients with 98 patients in the inpatient arm and 47 pa-
tients in the outpatient arm. The overall share of women
was 22.8 % with 21.4 % in inpatient care and 25.5 % in
outpatient care. Age ranged from 26 to 76 years, aver-
aging 55.6 years with 54.2 years in the inpatient arm and
56.2 years in the outpatient arm.
All valuations increased during the rehabilitation
phase and remained quite stable during the follow-up
period (Table 2). Compared with patients’ direct valua-
tions, TTO-based valuation was on average 24 points
higher at admission and then ranged between 14 and 17
points higher during FU (Fig. 1). The EHS-based value
set showed an almost eight point higher value at admis-
sion but, with a maximum of 1.4, was very close to the
reference valuation for the remaining measurements.
Both population-based value sets also showed smaller
variation than patients’ direct valuation over all meas-
urement points, with the GHS-based value set about a
quarter smaller and the EHS-based one about a fifth.
MAEs were found to closely match differences for the
GHS-based value set whereas, compared with the latter,
they were about halved for the EHS-based value set.
Pearson correlation with patients’ VAS was signifi-
cantly higher for the EHS-based value set than for the
GHS-based value set for all patients and for the in-
patient treatment arm; it was higher but with overlap-
ping confidence intervals for the outpatient treatment
arm (Fig. 2). This structure of results is found for both
absolute values as well as differences in values between
successive measurements. In the lower quartile of pa-
tients with regard to quality of life, correlation with ref-
erence values was significantly higher for the EHS-based
value set compared with the GHS-based one, for both
values and differences in valuations over time. For the
upper quarter of patients, correlations were just higher
but not significant (Table 3).
Correlations with MacNew global score were not
found to be significantly different for patients’ VAS and
the EHS-based value set, for both absolute values and
differences in valuations over time; yet both were signifi-
cantly lower for the GHS-based value set (Fig. 3). For
the EHS-based value set, correlation was above 0.7 for
absolute values but slightly below 0.5 for differences in
valuations over time.
Compared with quality-adjusted survival based on pa-
tients’ VAS, only the EHS-based approach did not differ
significantly in all patients as well as in the two treat-
ment arms (Fig. 4). However, for all patients (inpatients
and outpatients), utility-based QALYs were 20.3, 19.8,
and 20.8 % higher than quality-adjusted survival based
on patients’ own reports. The add-on effect of using
QALYs based on ex-ante choices corresponded to
54 days in perfect health for inpatients and 60 days for
outpatients. For quality-adjusted survival calculated from
the EHS-based value set, the respective add-on effects
were 1 and 9 days.
MAEs between both the EHS-based and the GHS-
based value sets and patients’ VAS differed most at
Table 2 Valuations by patients’ VAS and value sets, six observation points
Patients’ VAS GHS-TTO EHS-VAS
Patients Mean STD Mean STD Mean STD
Admission 145 65.1 19.0 89.1 16.9 72.9 15.8
Discharge 138 76.9 16.7 93.4 11.3 78.3 13.4
FU 3 months 135 77.4 15.8 91.7 14.5 77.5 13.8
FU 6 months 136 77.3 16.7 92.7 13.1 78.6 13.6
FU 9 months 128 79.1 15.0 94.9 9.3 80.5 11.4
FU 12 months 133 77.6 16.9 93.9 10.3 79.0 12.6
Legend: FU follow-up period after rehabilitation, STD standard deviation
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“admission”, with an increase of 50 % for the EHS-based
value set and 56 % for the GHS-based one. According to
the repeated measures regression, these time dependent
differences were significantly more pronounced for
younger patients. For the EHS-based value set, an add-
itional increase was found for patients with higher level
of education and for patients not living alone (Additional
file 1: Table S2). For the GHS-based value set, MAEs
were larger for patients with lower MacNew values at
baseline, over all observation points (Additional file 1:
Table S3).
Discussion
The counterfactual design of this re-analysis enabled
comparison with patients’ own valuations that were used
as a reference. In most analyses, the population-based
estimates of the EHS-based approach were found to
closely reproduce the reference of patient-reported valu-
ations. This was especially pronounced for the mean dif-
ferences between reference and value set, which also
reflect potential bias. It also notably existed for mean ab-
solute errors that integrate all individual variation. In
addition, differences in correlations for all patients and
Fig. 1 Differences between patients’ reported VAS and values sets, and mean absolute errors (MAEs). Legend: FU, follow-up period after rehabilitation.
Differences include respondents with EQ-5D descriptive system not fully completed but VAS reported, number of patients, see Table 1. MAEs include
complete responses only, number of patients by observation point: 139, 135, 131, 133, 126, 132
Fig. 2 Pearson correlation coefficients (ρ) with patients’ absolute VAS valuations and differences over time. Legend: Two value sets, all observation points;
inpatient rehabilitation n= 98, outpatient rehabilitation n= 47 at admission, otherwise varying number of patients; confidence intervals shown as error bars
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for subgroups investigated underscored the closer rela-
tion of the EHS-based value sets to patient-reported out-
come. As the standard used in economic evaluation
studies, the GHS-based value set was found to be sys-
tematically less strongly related to patients’ reports in-
cluding both absolute valuations and differences in
valuations over time, and also to render systematically
higher levels of overall patient benefit in terms of
quality-adjusted survival. The latter corresponds to earl-
ier findings that the GHS-based value set tends to
underestimate VAS values reported for health states with
severe problems, and to overestimate them for states
with no or moderate problems [9, 23]. In the present
study, the share of patients reporting a severe problem
in at least one of the EQ-5D dimensions was 7.6 % at ad-
mission, and reduced to 3.0 % at 12 months follow-up.
The GHS-based value set describes a larger gain for
these patients than they report on the VAS, thus contrib-
uting to a higher level of quality-adjusted survival.
EHS-based results were not only more strongly linked
to the benefits directly derived from patients, but even
showed lower dispersion than these reference values.
However, they were found not to reproduce valuation ap-
propriately directly after acute treatment for myocardial
infarction: At admission to rehabilitation, patients’ VAS
was much lower than the EHS-based approach. Acute
live-threatening experience may thus hardly be reflected
in the population sample from which the EHS-based value
set has been estimated. In particular, younger patients
with a higher level of education and not living alone
tended to report VAS values lower than the EHS-based
value set. The experience of these subgroups was not fully
reflected by estimates of population experience.
Patients analyzed had presented with different types of
acute cardiac events, although the study design does not
allow for extrapolation of findings to all post-acute heart
patients. A main methodological limitation of this study
is that the two national value sets used are based on
quite different concepts: GHS-based valuation is suited
to decision makers who intend to allocate money ac-
cording to ex-ante preferences of the population regard-
ing health. EHS-based valuation aims to derive patient
benefit from an average experience of a population sam-
ple. It is thus suited to decision makers whose priority is
to assess benefit from the patient’s perspective. Decision
makers have to make a normative choice about which
concept they want to use when appraising the evidence.
Given that the EHS-based value set is conceptually more
Table 3 Pearson correlation of value sets with patients’ VAS valuations and their differences
Lower quartile, patients’ VAS at admission Upper quartile, patients’ VAS at admission
Absolute values Differences Absolute values Differences
GHS-TTO Germany 0.460 (0.333–0.587) 0.233 (0.149–0.320) 0.285 (0.179–0.458) 0.188 (0.112–0.265)
EHS-VAS Germany 0.699 (0.603–0.788) 0.516 (0.430–0.597) 0.420 (0.258–0.571) 0.215 (0.116–0.316)
Legend: Confidence intervals in brackets
Fig. 3 Pearson correlation coefficients of all patients’ absolute VAS valuations with MacNew global score, and their differences over time. Legend:
Patients’ VAS and two value sets, all observation points, varying number of patients; confidence intervals shown as error bars
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closely related to the reference of patients’ VAS, it could
be expected that it may render better estimates for the
reference. It is well known that the TTO method tends
to produce higher values than VAS valuation, for ex-
ample when comparing national value sets based on
these two methods [1–3]. Quantifying the relative influ-
ence of valuation method (VAS, TTO) and type of
health state values (GHS, EHS) would have required
comparison of four types of value sets which were not
available. Yet, for a clinical study on heart rehabilitation
patients, three decision relevant points were elaborated
here by comparing patient-reported outcome with two
value sets: 1. it was shown to what extent traditional,
utility-based quality of life measurement and QALYs re-
flect patient benefit; 2. it was quantified to what extent
the normative choice between the two value sets affects
effectiveness outcome; and 3. it was shown that the
EHS-based value set offers an option to estimate
patient-reported outcomes while identifying situations in
which estimation is not accurate.
A methodological limitation is that the GHS-based
value set has been anchored for the state of being dead,
whereas the EHS-based concept could not be anchored
for consistency. Aside from methodological discussion
about anchoring [26], studies have shown that the im-
pact of anchoring on results may be minor in general
population samples [27], which is where the EHS-based
approach has been derived from.
Another important point is that the original SARAH
study only included patients from the German health
care system. The present study thus could not investi-
gate the transfer of quality of life results between health
systems. In order to fully quantify the transfer problem,
comparison between value sets of identical methodology
adapted to two health systems would be needed. Results
from an EHS-based value set may yet be used to check
whether the outcomes of a clinical study are sensitive to
the valuation approach. Decision makers can thus be in-
formed about whether or not valuation methods and
transfer problems may play a role in the assessment of
patient benefit.
A last conceptual limitation is that, with regard to a
specific health care system, only the valuation step has
been considered. A similar type of problem might even-
tually occur for the description of quality of life, al-
though this was not included in the scope of this study.
Conclusion
To jurisdictions responsible for market access, the con-
cept of valuing quality of life is an issue of salient rele-
vance. For a clinical intervention study, this analysis is,
to the best of our knowledge, the first to quantify the
impact on outcomes measured of using an EHS-based
value set instead of the traditional GHS-based approach.
Decision makers who consider patient relevant benefit
should especially take into account possible differences
between traditional economic utilities and patient-
reported outcomes.
The results provide a new option to those who give
priority to patient-reported outcomes and to results de-
rived from their target population: In order to adapt
quality of life results from clinical studies that have been
derived in other populations or have not been fully
based on patients’ reports, the EHS-based value set may
be used to estimate patients’ valuations. This appropri-
ately achieved, the resulting clinical endpoint may better
Fig. 4 Quality-adjusted survival for patients’ VAS and value sets. Legend: From admission to 12 months follow-up. Indicator reflects QALYs based
on ex-ante choices for GHS-TTO Germany and quality-adjusted survival based on experienced health for the other two indicators; confidence intervals
shown as error bars
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reflect patient benefit, and may thus bring closer to-
gether clinical and economic evaluations.
The performance of the EHS-based estimation is very
promising, but the results also indicated that, in situa-
tions close to acute vital events, estimates of general
population experience may not fully reproduce the
patients’ perspective. Yet, the performance of EHS-based
value sets in clinical populations different from the one
investigated here needs to be tested before use.
Additional files
An additional file shows tables giving an overview on
performance analysis and on repeated measures regres-
sion to explain absolute differences between the value
set and patients’ VAS [see Additional file 1.doc].
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Additional file 1: Table S1. Overview on performance analysis.
Table S2. Repeated measures regression to explain absolute
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